Biotricity Inc. released its quarterly earnings report for the period ending December 31, 2025. The company reported improved EBITDA and adjusted EBITDA for both the three- and nine-month periods ended December 31, 2025, with EBITDA increasing by nearly fivefold and adjusted EBITDA rising by over double. Management highlighted that these improvements are attributed to the company's focus on core operating activities, excluding non-cash items like share-based compensation and discretionary preferred stock dividend payments. Additionally, Biotricity reported a translation adjustment loss of 15 thousand for the quarter, compared to a loss of 77 thousand in the same period of the previous year. The company, which specializes in biometric data monitoring solutions for medical and healthcare markets, reaffirmed its commitment to delivering remote monitoring solutions focused on diagnostic and post-diagnostic care for lifestyle and chronic illnesses. However, management noted the existence of substantial doubt about the company's ability to continue as a going concern and disclosed that this concern was also noted by its independent registered public accounting firm.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-006211), on February 11, 2026, and is solely responsible for the information contained therein.